|
1
|
Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing.
|
J Virol
|
1986
|
4.91
|
|
2
|
NS3 is a serine protease required for processing of hepatitis C virus polyprotein.
|
J Virol
|
1993
|
4.60
|
|
3
|
The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase.
|
Virology
|
1991
|
4.07
|
|
4
|
Biosynthesis and biochemical properties of the hepatitis C virus core protein.
|
J Virol
|
1994
|
3.19
|
|
5
|
A mouse model for poliovirus neurovirulence identifies mutations that attenuate the virus for humans.
|
J Virol
|
1987
|
2.36
|
|
6
|
Identification of a new transcriptional initiation site and the corresponding functional gene 2b in the murine coronavirus RNA genome.
|
J Virol
|
1989
|
1.77
|
|
7
|
Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition.
|
Proc Natl Acad Sci U S A
|
1994
|
1.57
|
|
8
|
CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.
|
Cancer Gene Ther
|
2006
|
1.45
|
|
9
|
Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation.
|
Proc Natl Acad Sci U S A
|
1999
|
1.38
|
|
10
|
Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.
|
Proc Natl Acad Sci U S A
|
1999
|
1.32
|
|
11
|
Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector.
|
J Virol
|
1998
|
1.28
|
|
12
|
Biosynthesis, structure, and biological activities of envelope protein gp65 of murine coronavirus.
|
Virology
|
1989
|
1.19
|
|
13
|
In vitro study of the NS2-3 protease of hepatitis C virus.
|
J Virol
|
1997
|
1.18
|
|
14
|
Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.
|
J Virol
|
2000
|
1.13
|
|
15
|
In vivo gene transfer in mouse skeletal muscle mediated by baculovirus vectors.
|
Hum Gene Ther
|
2001
|
1.07
|
|
16
|
Targeted integration of adeno-associated virus-derived plasmids in transfected human cells.
|
Virology
|
1998
|
1.06
|
|
17
|
Significance of the immune response to a major, conformational B-cell epitope on the hepatitis C virus NS3 region defined by a human monoclonal antibody.
|
J Virol
|
1994
|
1.04
|
|
18
|
An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus.
|
Proc Natl Acad Sci U S A
|
2001
|
1.04
|
|
19
|
Development of animal models for adeno-associated virus site-specific integration.
|
J Virol
|
1999
|
1.04
|
|
20
|
A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein.
|
J Immunol
|
1993
|
1.02
|
|
21
|
Expression of the hepatitis delta virus large and small antigens in transgenic mice.
|
J Virol
|
1994
|
0.99
|
|
22
|
Expression of hepatitis C virus cDNA in human hepatoma cell line mediated by a hybrid baculovirus-HCV vector.
|
Virology
|
1999
|
0.94
|
|
23
|
Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis.
|
J Virol
|
2000
|
0.94
|
|
24
|
Natural evolution of coronavirus defective-interfering RNA involves RNA recombination.
|
Virology
|
1993
|
0.93
|
|
25
|
Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector.
|
Hum Gene Ther
|
2000
|
0.92
|
|
26
|
Gene electrotransfer results in a high-level transduction of rat skeletal muscle and corrects anemia of renal failure.
|
Hum Gene Ther
|
2000
|
0.92
|
|
27
|
Intratumor RNA interference of cell cycle genes slows down tumor progression.
|
Gene Ther
|
2011
|
0.88
|
|
28
|
Antitumor activity of recombinant adenoviral vectors expressing murine IFN-alpha in mice injected with metastatic IFN-resistant tumor cells.
|
Cancer Gene Ther
|
2001
|
0.86
|
|
29
|
Murine coronavirus gene 1 polyprotein contains an autoproteolytic activity.
|
Adv Exp Med Biol
|
1990
|
0.85
|
|
30
|
Towards the use of baculovirus as a gene therapy vector.
|
Curr Opin Mol Ther
|
2001
|
0.84
|
|
31
|
Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector.
|
Gene Ther
|
2001
|
0.84
|
|
32
|
CD8+ T-cell tolerance can be broken by an adenoviral vaccine while CD4+ T-cell tolerance is broken by additional co-administration of a Toll-like receptor ligand.
|
Scand J Immunol
|
2006
|
0.82
|
|
33
|
A human antibody specific for hepatitis C virus core protein: synthesis in a bacterial system and characterization.
|
Gene
|
1995
|
0.82
|
|
34
|
Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells.
|
Scand J Immunol
|
2005
|
0.80
|
|
35
|
Tamarin alpha-interferon is active in mouse liver upon intramuscular gene delivery.
|
J Gene Med
|
2001
|
0.78
|
|
36
|
An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
|
Cancer Gene Ther
|
2008
|
0.78
|
|
37
|
Gene therapy of Hunter syndrome: evaluation of the efficiency of muscle electro gene transfer for the production and release of recombinant iduronate-2-sulfatase (IDS).
|
Biochim Biophys Acta
|
2008
|
0.77
|
|
38
|
Non-viral transfer approaches for the gene therapy of mucopolysaccharidosis type II (Hunter syndrome).
|
Acta Paediatr Suppl
|
2002
|
0.75
|
|
39
|
Recombinant human antibodies specific for hepatitis C virus proteins.
|
Arch Virol
|
1997
|
0.75
|
|
40
|
Murine hepatitis virus JHM variants isolated from Wistar Furth rats with viral-induced neurological disease.
|
Adv Exp Med Biol
|
1990
|
0.75
|